Professor Mahin Khatami, PhD @ IPAK-EDU Science Webinar This Monday, 5/8/2023, 7pm ET

"Cancer and Vaccines: Influence on Mitochondria and Immune Neuroplasticity"

Join us Monday, May 8, 2023, at 7pm ET in the IPAK-EDU Director’s Science Webinar.

"Cancer and Vaccines: Influence on Mitochondria and Immune Neuroplasticity"

Dr. Khatami’s Biography:

A. Education and Training:

Chemistry (BS); Science Education (MS) from Tehran, Iran. 1969, immigrated to USA; Biochemistry (MA, SUNY at Buffalo); Molecular Biology-Protein Chemistry (PhD, 1980, University of Pennsylvania, UPA).

1980-1985--Postdoctoral trainings and research associate in physiology (UVA); protein chemistry (proteomics), Fox Chase Cancer Institute and UPA; diabetes and immunology, UPA.

B. Highlights of Discoveries and Research Accomplishments at University of Pennsylvania (UPA):1980s--Research Faculty of Medicine, Department of Ophthalmology, University of Pennsylvania. At UPA, Khatami quickly earned supervisory responsibilities on two major projects; cell and molecular biology of diabetic retinopathy/maculopathy, and experimental models of acute and chronic ocular inflammatory diseases. She also collaborated with scientists at Department of Anatomy at UPA, on embryonic muscle development.

In her first decade of junior academic career, Khatami was considered as the most productive scientist in USA; published 39 articles in peer-reviewed journals and book chapters and over 60 abstracts in conference proceedings.

In 1998, Khatami joined the National Cancer Institute (NCI), Division of Cancer Prevention (DCP), the National Institutes of Health (NIH). She was Program Director (Health Scientist Administrator, HSA), involved in developing molecular concepts for cancer diagnostic (biomarkers) and utilization of patient biospecimen for large clinical trials such as Prostate-Lung-Colorectal Ovarian (PLCO) Cancer Screening Trials.

Extension of her earlier ‘accidental’ discoveries at UPA in 1980’s, on models of inflammatory diseases became closely relevant to her duties. She submitted a series of novel proposals for molecular diagnosis, prevention and therapy of cancer and designs of cohort clinical trials.

C. Highlights of Scientific Challenges at NCI/NIH:

Results of Khatami’s pioneering studies on experimental models of acute and chronic inflammatory diseases are the first and only series of evidence for direct link between inflammation and time-course kinetics of developmental phases of immune dysfunction toward multistep tumorigenesis and angiogenesis in conjunctival associated lymphoid tissues.

At NCI/NIH, Khatami’s challenging efforts to continue and promote her pioneering studies on the important role of inflammation in cancer research, initially met with severe opposition, denial, minimization and rejection of submitted concepts, comprehensive proposals and lectures by upper managers at NCI/NIH. However, in last couple of decades, these efforts seem awakened the entire cancer community around the world. Significant increase in the number of federally funded projects are focused on numerous fragmented ideas that Khatami proposed used on in vivo and in vitro models of site-specific cancers, identification of inflammatory mediators, genetic mutations; and related expensive technologies for diagnosis and drug development within and outside NCI/NIH. Unfortunately, reductionist approaches to cancer biology and inflammation research created tremendous chaos, misunderstanding, misinformation, controversies and ongoing debates of what inflammation does; whether it prevents cancer or it causes carcinogenesis.

Invention: In 2005, Khatami published an NCI-Invention (Federal Register, 2005); standardizing cancer biomarkers criteria (data elements, Research Tool) as a foundation of developing a cancer biomarkers database for oncology research. An inflammatory mediator (M-CSF) was identified as prototype to test/tailor data elements; for comparison of its superior sensitivity and specificity with other traditional cancer markers.

Dr. Khatami served as president and VP for Graduate Women in Science (GWIS) Omicron Chapter; scientific judge; consultant to pharmaceutical companies; member of professional societies; editorial activities; symposia organizer and invited lecturer internationally. She was Associate Editor for Cell Biochemistry and Biophysics and Guest Editor on Special Topic of Bioenergetics for journal of Clin Trans Med.

Her last position at NCI/NIH was Director, Innovative Molecular Analysis Technology (IMAT) Program, and Assistant Director for Technology Program Development, Office of Technology and Industrial Relations, Office of the Director, NCI/NIH.

Topics of her studies and publications included glucose toxicities relating to active and passive transport of glucose, ascorbate, myoinositol; enzymes activities on cell/molecular biology of in vitro and in vivo models of diabetes complications; embryonic muscle development; immunobiology of ocular inflammatory diseases (innate and adaptive immune cells activities, histamine, prostaglandins biosynthesis); drug evaluation for diabetes, inflammatory diseases and tumorigenesis.

D. Current Professional Activities:

Since retirement, Professor Khatami published 4 books and several articles relating to the role of inflammation-immunity in health and age-associated diseases, cancer biology and vaccine sciences.

Currently, she serves as expert Immunologist for vaccine legal cases. She is also a selected reviewer for SciPinion to re-evaluate published data on immune toxicities of environmental, industrial and chemical hazards that influence public health.

In her recent publications, Dr. Khatami expressed serious concerns about government mandate on over-vaccination of unborn, newborn, infant or immunecompromised individuals with pathogen-specific vaccines. She demonstrated that pathogen-specific vaccination that are made in toxic media are the likely causes, exacerbations and consequences of significant increase in childhood and adult diseases in the last few decades, particularly in America. She has also challenged the validity of heavy investment on genetics (‘inheritance’) as origins of diseases.

In 2022, Khatami was invited to testify before Maryland Health Committee on scientific concerns about safety of mask mandate and pathogen-specific vaccines, including heavy propaganda on injection of public with dangerous mRNA or DNA spike proteins that are claimed as Covid 19 vaccines.

Selected References in 2022 and 2023.

Khatami M: Immune Neuroplasticity (Power Within, Adaptive, Horizontal) is Weakened by Vaccines and Drugs (Power Without): Mitochondrial Sink Holes, Genomic Destabilization and Immune Disorders-Hypothesis

Garvey GJ, Anderson JK, Goodrum PE, Tyndall KH, Cox LA, Khatami M, Morales-Montor J, Schoeny RS, Seed JG, Tyagi RK, Kirman CR, Hays SM. Weight of evidence evaluation for chemical-induced immunotoxicity for PFOA and PFOS: findings from an independent panel of experts. Crit Rev Toxicol. 2023 Apr 28:1-18. doi: 10.1080/10408444.2023.2194913. Epub ahead of print. PMID: 37115714. Weight of evidence evaluation for chemical-induced immunotoxicity for PFOA and PFOS: findings from an independent panel of experts - PubMed (nih.gov).